Monitor commercial launch execution and prescription uptake in H2 2026. The approval is a positive pipeline catalyst but not transformative for GSK's top line. Spero Therapeutics (SPRO) may see a more pronounced move given its smaller market cap and reliance on this asset.
Price Chart
Executive Summary
GSK announces FDA approval of Utebzi (tebipenem pivoxil), the first oral carbapenem antibiotic for complicated urinary tract infections (cUTIs) in adults. The approval is based on the PIVOT-PO phase III trial demonstrating non-inferiority to intravenous imipenem-cilastatin. This expands GSK's anti-infectives portfolio and addresses a significant unmet need, though near-term financial impact is modest relative to GSK's $106.5B market cap.
Key Facts
- FDA approved Utebzi (tebipenem pivoxil) for cUTIs including pyelonephritis in adults with limited/no oral alternatives.
- First and only oral carbapenem antibiotic approved in the US.
- PIVOT-PO trial showed 58.5% overall success rate for tebipenem pivoxil vs 60.2% for IV imipenem-cilastatin (adjusted difference -1.3%; 95% CI -7.5%, 4.8%).
- Product anticipated to be available to US patients by end of 2026.
- Approval builds on GSK's exclusive global licensing agreement with Spero Therapeutics (Nasdaq: SPRO) from September 2022.
Financial Impact
No specific revenue guidance provided; addresses a US market with >3 million annual cUTI cases and >$6 billion in annual healthcare costs. Modest near-term contribution to GSK's overall revenue.
Risk Factors
- Pricing and reimbursement challenges in the US antibiotic market.
- Competition from existing IV carbapenems and other oral antibiotics for cUTI.
- Adoption may be limited to patients with no alternative oral options per label.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-006036 |
| Document: 0001654954-26-006036-index-headers.html | 0001654954-26-006036 |
| Document: 0001654954-26-006036-index.html | 0001654954-26-006036 |
| Document: 0001654954-26-006036.txt | 0001654954-26-006036 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 6-K | $50.01 $50.22 | ▲ +0.42% | ▼ −0.40% | $47.03 (−5.96%) |
Sep 14, 2026 18d ago | 6-K | $50.05 $51.08 | ▲ +2.06% | ▲ +1.95% | $47.03 (−6.03%) |
Sep 14, 2026 18d ago | 6-K | $50.05 $51.08 | ▲ +2.06% | ▲ +1.95% | $47.03 (−6.03%) |
Sep 11, 2026 21d ago | 6-K | $48.13 $50.22 | ▲ +4.34% | ▲ +4.56% | $47.03 (−2.29%) |
Sep 10, 2026 22d ago | 6-K | $48.12 $51.06 | ▲ +6.11% | ▲ +6.61% | $47.03 (−2.27%) |
Sep 10, 2026 22d ago | 6-K | $48.12 $51.06 | ▲ +6.11% | ▲ +6.61% | $47.03 (−2.27%) |
Sep 1, 2026 4w ago | 6-K | $50.66 $48.63 | ▼ −4.01% | ▼ −4.09% | $47.03 (−7.17%) |
Sep 1, 2026 4w ago | 6-K | $50.66 $48.63 | ▼ −4.01% | ▼ −4.09% | $47.03 (−7.17%) |
Aug 26, 2026 5w ago | 6-K | $51.43 $50.44 | ▼ −1.92% | ▼ −1.80% | $47.03 (−8.56%) |
Aug 24, 2026 5w ago | 6-K | $51.78 $50.25 | ▼ −2.95% | ▼ −3.42% | $47.03 (−9.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access